A Comparison of [68Ga]DOTATATE and [18F]AmBF3TATE for the Staging and Assessment of Neuroendocrine Malignancies
Opening soon NCT07621146
Run by British Columbia Cancer Agency · for 18 and older · All sexes
What this study is about
Neuroendocrine tumours (NETs) are generally slow growing, but some can be aggressive and resistant to treatment. Compared to healthy cells, the surface of these tumor cells has a greater number of molecules called somatostatin receptors (SSTR) which requires specific PET scan tracers to sufficiently capture on images. The current standard of care tracer at BC Cancer for SSTRs on NETs is 68Ga-DOTATATE. This project seeks to identify if 18F-AmBF3-TATE (a tracer that has established safety from phase 1 trial results), is comparable in disease detection, no. of lesions identified, image quality, safety and overall accuracy, to 68Ga-DOTATATE.
Who can join (things the study team will check)
✅ You may be able to join if…
- Age ≥18 years
- Patients referred for and meeting institutional criteria for a [68Ga]DOTATATE PET/CT for the investigation of a known or suspected neuroendocrine malignancy (BC Cancer criteria APPENDIX A).
🚫 You may not be able to join if…
- Pregnant and breast-feeding patients.
- Patients unwilling or unable to undergo a second PET/CT.
- Patients exceeding the safe weight limit of the scanner (204.5 kg) or who cannot fit through the PET/CT bore (70cm diameter).
Where this trial is running
- BC Cancer Vancouver, Vancouver, British Columbia, Canada
Who to contact
Research Project Manager · 604-675-8000 · MITclinicaltrials@bccancer.bc.ca
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT07621146.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.